| Summary of Segment Profit or Loss and Expenses |
The table below is a summary of the segment profit or loss, including significant segment expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended
June 30, |
|
|
Six months ended
June 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
|
|
|
|
|
(in thousands) |
|
Research and Development |
|
|
|
|
|
|
|
|
|
|
|
|
Manufacturing and technical operations |
|
$ |
242 |
|
|
$ |
17,084 |
|
|
$ |
9,263 |
|
|
$ |
30,795 |
|
Clinical |
|
|
683 |
|
|
|
5,854 |
|
|
|
7,180 |
|
|
|
9,980 |
|
Preclinical |
|
|
210 |
|
|
|
256 |
|
|
|
1,140 |
|
|
|
526 |
|
Employee-related costs |
|
|
3,429 |
|
|
|
7,635 |
|
|
|
11,513 |
|
|
|
14,366 |
|
Facilities and other operating costs |
|
|
1,239 |
|
|
|
4,420 |
|
|
|
4,613 |
|
|
|
7,937 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and Administrative |
|
|
|
|
|
|
|
|
|
|
|
|
Consultants and other outside services |
|
|
1,877 |
|
|
|
3,751 |
|
|
|
4,519 |
|
|
|
7,348 |
|
Employee-related costs |
|
|
880 |
|
|
|
3,669 |
|
|
|
4,044 |
|
|
|
6,903 |
|
Facilities and other operating costs |
|
|
1,943 |
|
|
|
1,735 |
|
|
|
2,828 |
|
|
|
2,898 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring, impairment, and costs of suspended
programs |
|
|
37,098 |
|
|
|
— |
|
|
|
83,378 |
|
|
|
— |
|
Stock-based compensation expense |
|
|
5,258 |
|
|
|
4,302 |
|
|
|
12,134 |
|
|
|
8,206 |
|
Depreciation expense |
|
|
40 |
|
|
|
612 |
|
|
|
712 |
|
|
|
1,165 |
|
Total operating expense |
|
|
52,899 |
|
|
|
49,318 |
|
|
|
141,324 |
|
|
|
90,124 |
|
Loss from operations |
|
|
(52,899 |
) |
|
|
(49,318 |
) |
|
|
(141,324 |
) |
|
|
(90,124 |
) |
Interest income |
|
|
3,269 |
|
|
|
4,987 |
|
|
|
7,207 |
|
|
|
9,992 |
|
Other expense, net |
|
|
(307 |
) |
|
|
(17 |
) |
|
|
(318 |
) |
|
|
(27 |
) |
Net loss |
|
$ |
(49,937 |
) |
|
$ |
(44,348 |
) |
|
$ |
(134,435 |
) |
|
$ |
(80,159 |
) |
|